This invention relates generally to the field of cancer diagnostics, and in particular to the detection of an increased risk of developing a skin cancer. Specifically, the present invention relates to a method of detecting and identifying an increased risk of developing a skin cancer in a human patient based on polymorphisms of the GRHL3 gene. The present invention is useful in medical diagnostics, and cancer risk screening.
Patents were granted in Australia, USA and Europe, validated in United Kingdom. Nencki Institute is the sole applicant.
For more information contact Technology Transfer Office.